Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP ‐1 receptor agonists: A prospective observational study
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70537 ↗At a glance
Beobachtungsstudie in Diabetes, Obesity and Metabolism, 2026. Written by Xiao-Yu Li and 11 co-authors. Institution: Department of Anesthesiology, Ningbo No.2 Hospital, Ningbo, China. Major MEDLINE topics: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Cited 4 times so far (Crossref); 35 references. Funded by: Medical Scientific Research Foundation of Zhejiang Province, China, Zhejiang Provincial Public Service and Application Research Foundation, Ningbo Medical and Health Brand Discipline.
Topics: Diabetes mellitus
Abstract (original language)
Aims
To assess the prevalence and risk factors of increased residual gastric content (RGC) under fasting conditions in patients with type 2 diabetes mellitus (T2DM) treated with glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), providing evidence for peri‐procedural medication management. Materials and methods This single‐centre prospective cohort study enrolled inpatients with T2DM at the Endocrinology Department of Ningbo No.2 Hospital between April and December 2024. Patients aged 18–80 years with BMI 1.5 mL/kg. Secondary analyses explored associated risk factors.
Results
Of 390 patients included (237 [60.8%] male), 224 (57.4%) were GLP‐1 RA users. After propensity score matching, the prevalence of increased RGC remained significantly higher in GLP‐1 RA users compared with non‐users (53.3% vs. 32.1%; p < 0.001). In multivariate logistic regression adjusted by inverse probability of treatment weighting (IPTW), GLP‐1 RA use was robustly associated with increased RGC (OR 2.52; 95% CI 1.84–3.45). Notably, diabetic retinopathy (OR 1.84; 95% CI 1.14–2.99) and diabetic kidney disease (OR 1.67; 95% CI 1.17–2.39) emerged as independent risk factors, identifying a high‐risk microvascular phenotype. Furthermore, among GLP‐1 RA users, each additional day since the last GLP‐1 RA dose reduced the odds of increased RGC by 23% (adjusted OR 0.77; 95% CI 0.65–0.90).
Conclusions
GLP‐1 RA therapy is a potent, independent driver of significant gastric retention in patients with T2DM, persisting despite standard fasting. Crucially, the presence of diabetic retinopathy or nephropathy identifies a “double‐hit” high‐risk phenotype, where pharmacological delay interacts with microvascular burden. These findings suggest that current fasting protocols may be insufficient for these patients, necessitating individualized preoperative assessment based on microvascular status and dosing timing.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Anesthesiology, Ningbo No.2 Hospital, Ningbo, China.
- Department of Anesthesiology, Fenghua District People's Hospital, Ningbo, China.
- Department of Anesthesiology, Zhenhai Hospital of Traditional Chinese Medicine, Ningbo, China.
- Center for Disease Control and Prevention of Zhenhai District, Ningbo, China.
- Department of Endocrinology, Ningbo No.2 Hospital, Ningbo, China.
- Department of Anesthesiology, Ningbo Hangzhou Bay Hospital (Ningbo Branch of Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai), Ningbo, China.
ORCID profiles: Bo Lu
Funding
- Medical Scientific Research Foundation of Zhejiang Province, China
- Zhejiang Provincial Public Service and Application Research Foundation
- Ningbo Medical and Health Brand Discipline
- Second Batch Agricultural and Technology Plan Projects in Fenghua District for the Year 2024
- Medical Science and Technology Program Project of Zhenhai District Health Bureau
Cite
APA
Li, X. Y., Jin, Y., Feng, X. Y., Wang, R. C., Zeng, F. F., Qin, J. L., Li, J. H., Xia, J. Y., Mo, Y. P., Zhai, X. J., Chen, J. P., & Lu, B. (2026). Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP ‐1 receptor agonists: A prospective observational study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70537
Vancouver
Li XY, Jin Y, Feng XY, Wang RC, Zeng FF, Qin JL, et al. Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP ‐1 receptor agonists: A prospective observational study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70537
BibTeX
@article{Li2026,
author = {Li, Xiao-Yu and Jin, Yun and Feng, Xiu-Ye and Wang, Rui-Chun and Zeng, Fan-Fu and Qin, Jin-Ling and Li, Jian-Hui and Xia, Jin-Ying and Mo, Ye-Ping and Zhai, Xiao-Jie and Chen, Jun-Ping and Lu, Bo},
title = {Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP ‐1 receptor agonists: A prospective observational study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70537}
}
EUVIMED